

Claims

What is claimed is:

- 5 1. The use of N-[(1-acryloylpiperidin-4-yl)methyl]-5-(4-phenoxyphenyl)pyrimidine-4,6-diamine **(1)**; 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)-4-fluoropiperidin-1-yl)prop-2-en-1-one **(2)**; or a pharmaceutically acceptable salt, a pharmaceutically acceptable tautomer, or a pharmaceutically acceptable stereoisomer thereof, for use in the manufacture of a medicament for treating
10 multiple sclerosis (MS).
2. The use according to claim 1, wherein the MS is selected from relapsing MS (RMS), relapsing-remitting MS (RRMS), progressive MS (PMS), secondary-progressive MS (SPMS), primary-progressive MS (PPMS), and progressive-relapsing MS (PRMS).
15
3. The use of N-[(1-acryloylpiperidin-4-yl)methyl]-5-(4-phenoxyphenyl)pyrimidine-4,6-diamine (1); 1-(5-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)-4-fluoropiperidin-1-yl)prop-2-en-1-one (2); or a pharmaceutically acceptable salt, a
20 pharmaceutically acceptable tautomer, or a pharmaceutically acceptable stereoisomer thereof, for use in the manufacture of a medicament to prevent multiple sclerosis (MS).
4. The use according to claim 3, wherein the MS is selected from relapsing MS (RMS), relapsing-remitting MS (RRMS), progressive MS (PMS), secondary
25 progressive MS (SPMS), primary-progressive MS (PPMS), and progressive-relapsing MS (PRMS).